Status:
COMPLETED
Decongestant Effect, Timing of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold
Lead Sponsor:
Novartis
Conditions:
Common Cold
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The aim of this study is to characterize the time profile of the decongestant properties of xylometazoline and to investigate its effect on sleep, general well-being and smell/taste.
Eligibility Criteria
Inclusion
- Over 18 years
- Have had moderate common cold symptoms for less than 36 hours.
Exclusion
- Congested/runny nose for more than two continuous weeks in the previous 12 months
- Deviated septum or nasal polyps
- Recent use of antibiotics
- Recent sinusitis
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00452270
Start Date
March 1 2007
End Date
April 1 2007
Last Update
May 3 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Cardiff, Wales, United Kingdom